about
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialEvaluation and consequences of heterogeneity in the circulating tumor cell compartmentAdjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step ForwardExosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practiceMultisciplinary management of patients with liver metastasis from colorectal cancerPanitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 studyWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerPhase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.Targeting Angiogenesis in Biliary Tract Cancers: An Open OptionAnti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study.Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomasTowards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and HypoxiaThe radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein.Familial and sporadic inflammatory bowel disease: different entities?Digestive oncologist in the gastroenterology training curriculum.Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays.Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab.Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric studyClustering of increased small intestinal permeability in families with Crohn's disease.A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.Cancer and the microbiome: potential applications as new tumor biomarker.18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract.Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathyTumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.Psychometric evaluation of the FACT Colorectal Cancer Symptom Index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulnessGenome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasisHealth-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment.Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.Recombinant human erythropoietin alpha modulates the effects of radiotherapy on colorectal cancer microvessels.Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
P50
Q21261279-5DD43AD1-A649-42DC-81BF-CDDF18A31623Q26765357-D0500353-29FA-4B69-98E8-E958096F89E2Q26858776-5EEC0693-04E8-442B-B485-791CF97B0655Q28066211-3595CC3F-78BB-4858-ABEB-F28D2AE174FDQ28069575-B9002E92-C7FA-4D25-A3BE-5A75B9B2CA35Q28238311-FCCE2F4E-2319-410B-A459-5BC3F98EDF58Q28271324-F749D8F4-8611-4C65-BA37-860665DF006EQ30313606-095ECB1E-5425-4A37-B7E9-158604480F11Q30398807-F5D68A38-CED5-4B0C-B01F-A9668A55E39CQ32099571-169E7E30-A737-4573-8CEE-C654149E0B4FQ33168544-CEC90CD4-B679-4BFD-9161-BE317650ED40Q33365031-63AE531C-F6A5-43DA-90DD-569649EB99F8Q33367733-9D0992A3-0B82-41B4-999A-6989A632B846Q33384594-381F1E1D-80D7-473A-B367-4912D0E7421CQ33575439-EAC581E2-F5E7-49B1-AE31-B08F00132AC0Q33820876-02F07468-6123-4274-B499-04AFAB81A16DQ34123758-5952C23B-7D01-43CC-869D-FCC2BE8EC577Q34125551-4CD9804D-1D88-442F-8177-389DA1A3C21CQ34183862-318813E5-1DDD-4146-A12F-961C5C8267B7Q34456201-6E2106EC-3EB7-43B9-8938-0AEBBF20642DQ34508065-589DDDA8-30F6-425A-B46B-13BA159DEEB2Q34624122-DA8E1CB0-0AB2-484D-95D7-AD9921D368F7Q34633373-9E53E95F-49E6-4B38-AF33-A61781604A71Q34657372-A3DEB406-E69F-41CD-9D5F-1B876B965307Q34658519-634FD060-89BF-42D4-A295-D54ECD143411Q34669169-85F4B9BF-BBA4-4107-B0F9-31EEB56675B2Q34742820-F0123421-C366-4FA0-A815-341E270BC0F9Q35034768-31E25071-B1A7-44CE-A902-062D44A7DAEEQ35508820-3AB2E2E9-FE27-49F9-8DAA-245D838D2637Q35546839-D843FA30-827A-4FD4-97E7-0C130A4BE0F2Q35552641-496B5802-EE22-4D8E-9DC0-19CC375AE763Q35582297-F15D2DF5-543D-42B8-AD26-76511A5D3257Q35583945-C7979E06-01CB-4591-8F58-7B1B814A6B57Q35596623-4F554F0E-2F3C-4240-92AF-E05C8FC4E11EQ35623078-86D88DD4-E0FB-4EA3-AA2D-1AACF08F6256Q36452263-48E4CCF8-546E-4D0C-8EB5-8E5A757D4B9DQ36610013-79D396A3-4C29-4900-913E-7EA77B325C82Q36610680-DA5F6B34-72AB-4AFB-82FB-8E022604BEE9Q36671874-961002D4-C3A4-4824-A1FA-ADF0D5646B54Q36719024-1907BD79-A331-456D-BF30-13420E9C6D13
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marc Peeters
@ast
Marc Peeters
@en
Marc Peeters
@es
Marc Peeters
@nl
Marc Peeters
@sl
type
label
Marc Peeters
@ast
Marc Peeters
@en
Marc Peeters
@es
Marc Peeters
@nl
Marc Peeters
@sl
prefLabel
Marc Peeters
@ast
Marc Peeters
@en
Marc Peeters
@es
Marc Peeters
@nl
Marc Peeters
@sl
P106
P21
P31
P496
0000-0003-4969-2303
P569
2000-01-01T00:00:00Z